ITGB1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population engineered to disrupt the ITGB1 gene in Jurkat T lymphocytes. This pooled knockout model provides a loss-of-function system for investigating integrin ??1-mediated processes without the requirement for clonal isolation, thereby capturing population-level heterogeneity.
The Jurkat cell line is an immortalized human T lymphocyte originally derived from a 14-year-old male with acute T-cell leukemia. Jurkat cells are widely employed as a model for T-cell receptor signaling, activation, and leukemogenesis due to their well-defined signaling networks and ease of culture. This background makes them an ideal host for CRISPR-based gene disruption to study T-cell biology and cancer.
ITGB1 encodes integrin ??1, which heterodimerizes with ?? integrins such as ITGA4 and ITGA5 to form receptors for fibronectin, laminin, and collagen. Ligand binding triggers outside-in signaling by inducing FAK autophosphorylation and recruitment of Src family kinases. This FAK-Src complex phosphorylates downstream adaptors like paxillin and activates the PI3K/AKT and MEK/ERK cascades. The pathway is further regulated by inside-out signals from the T-cell receptor (TCR), which promote integrin activation through Talin and Kindlin binding to the ??1 cytoplasmic tail. Downstream, RhoA GTPase and actin cytoskeleton remodeling are orchestrated to drive cell adhesion, migration, and survival.
In Jurkat cells, disruption of ITGB1 severely impairs adhesion to fibronectin, leading to reduced FAK, AKT, and ERK1/2 phosphorylation. Consequently, integrin-dependent processes such as T-cell homing, migration, and adhesion-mediated survival are compromised. Additionally, TCR-integrin crosstalk and immune synapse stability are disrupted, impairing T-cell activation. The polyclonal knockout population avoids clonal bias, providing a robust model to quantify these functional deficits across a heterogeneous cell pool.
Key applications include studying integrin ??1 roles in T-cell adhesion and migration, screening for integrin-targeted therapeutics, investigating leukemic cell dissemination, and examining immune synapse formation. Common assays employed are western blotting for ITGB1, phospho-FAK (Tyr397), and phospho-AKT (Ser473); flow cytometry to quantify surface integrin expression; cell adhesion assays on fibronectin; Boyden chamber migration assays; phospho-signaling analysis; and live-cell imaging of adhesion dynamics. Additionally, these cells are amenable to drug sensitivity assays using integrin inhibitors. For further technical information or custom requests, please contact Ascent Research.
